Compound Specifications CAS 137525-51-0 MW 1,419.53 Da Documentation & Lab Use Form: Lyophilized research material Documentation: Review the product label, batch records, and applicable laboratory SOPs before accessioning
Multivariate analysis revealed some predictive factors of 90 th -day poor clinical outcomes, including older age (OR 1.12, p = 0.007), male sex (OR 14.56, p = 0.023), predominant hemisphere lesion (OR12.30, p = 0.026), increased NIHSS of 2 points (OR 34.47, p = 0.006), and large artery atherosclerosis classification (OR 13.08, p = 0.016)
AOD-9604 however failed to induce significant weight loss in a 24-week trial of 536 subjects and its development as an anti-obesity agent was terminated (214)
Quality: USP Grade, sterile, and non-pyrogenic, ensuring safety for parenteral administration